Remdesivir and the Liver: A Concise Narrative Review of Remdesivir-Associated Hepatotoxicity in Patients Hospitalized Due to COVID-19
Severe acute respiratory syndrome coronavirus 2 has infected millions of people, but about 20% of infected individuals do not develop symptoms. COVID-19 is an inflammatory disease that affects a portion of individuals infected with the virus and it is associated with liver injury and other complicat...
Main Authors: | Alireza FakhriRavari, Mazyar Malakouti |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-02-01
|
Series: | Pharmacoepidemiology |
Subjects: | |
Online Access: | https://www.mdpi.com/2813-0618/3/1/5 |
Similar Items
-
Remdesivir, compuesto con potencial terapéutico contra SARS-CoV-2
by: Anthony Paul Bautista-Pariona, et al.
Published: (2021-02-01) -
Differential cytokine responses in hospitalized COVID-19 patients limit efficacy of Remdesivir
by: Chan, Yi-Hao, et al.
Published: (2022) -
Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?
by: Mekonnen Sisay
Published: (2020-05-01) -
Incidence and potential risk factors for remdesivir-associated bradycardia in hospitalized patients with COVID-19: A retrospective cohort study
by: Yazed Saleh Alsowaida, et al.
Published: (2023-02-01) -
Assessing in vitro stability of remdesivir (GS-5734) and conversion to GS-441524 in feline plasma and whole blood
by: Sally J. Coggins, et al.
Published: (2024-12-01)